Sep 13, 2022 / 12:00PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
All right. Perfect. I think we are ready to go. Good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have Genmab with us this morning.
Briefly before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.
So with that, I'm pleased to have Jan van de Winkel, the CEO of Genmab; and Anthony Pagano, who is the CFO. Jan, I thought maybe a good place to start would be to talk about epco and maybe just update people on where we are in terms of filing and path to market there.
Questions and Answers:
Jan G.J. van de Winkel - Genmab A/S-Co-Founder - President & CEOThanks for having us here today. We
Trustpilot
